Clinical trials: Lupus Erythematosus
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis
To demonstrate that the treatment effect in lupus nephritis of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.
- Trial name
- NCT02256150
- Testing
- Mizoribine (MZR), Cyclophosphamide (CTX)
- Where
- 26 sites in China
- Volunteers
- 250 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Autoimmune Diseases, Rheumatoid Arthritis (RA)
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
This is a multi-center, open-label Ph 1b basket study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, biomarker response, and preliminary efficacy of multiple doses of S-4321 in…
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Psoriasis (PsO)
- Trial name
- NCT07455578
- Testing
- S-4321
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Seismic Therapeutic AU Pty Ltd
Systemic Lupus Erythematosus
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus
- Trial name
- NCT02307643
- Testing
- MT-1303 Low dose, MT-1303 High dose
- Where
- 14 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Tanabe Pharma Corporation
Systemic Lupus Erythematosus
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
This study will evaluate the efficacy and safety of MIL62 compared with placebo in participants with systemic lupus erythematosus.
- Trial name
- NCT07405970
- Testing
- MIL62
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
Lupus Nephritis
Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis
The aim of the open multi-center study is to determine an efficient and safe dose and dosing schedule of NKT-01 in induction of response in treatment of lupus nephritis.
- Trial name
- NCT00709722
- Testing
- NKT-01
- Where
- 6 sites in Czechia, Germany
- Volunteers
- 21 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Lupus Erythematosus, Systemic, Lupus Erythematosus
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
To compare the effect of RAYOS® versus immediate-release (IR) prednisone on fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
- Conditions
- Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue
- Trial name
- RIFLE (NCT03098823)
- Testing
- RAYOS, Prednisone
- Where
- 21 sites in United States
- Volunteers
- 62 people
- Sponsor
- Ampel BioSolutions, LLC
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
This Phase 1, open label, dose escalation study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of HB2198, a tetravalent bispecific anti CD19/CD20 antibody, in adults with…
- Conditions
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)
- Trial name
- NCT07491900
- Testing
- HB2198
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Hinge Bio
Systemic Lupus Erythematosus
ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)
To explore the potential for use of DxTerity's AIP IFN-1 test as personalized guided care and monitoring module in patients with Systemic lupus erythematosus(SLE) using consented patient health information
- Trial name
- ELEVATE (NCT05347992)
- Where
- United States
- Volunteers
- 423 people
- Sponsor
- DxTerity Diagnostics
SLE, SLE (Systemic Lupus)
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
- Trial name
- NCT06613360
- Testing
- CLN-978
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 24 people
- Sponsor
- Cullinan Therapeutics Inc.
Lupus Erythematosus, Systemic
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).
- Trial name
- ADDRESS II (NCT01972568)
- Testing
- Atacicept 75 milligram (mg), Atacicept 150 mg
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Lupus Nephritis
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis
- Trial name
- NCT06717815
- Testing
- IPG11406
- Where
- 17 sites in China
- Volunteers
- 24 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Systemic Lupus Erythematosus
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Trial name
- NCT07011043
- Testing
- Budoprutug
- Where
- 18 sites in United States, Bulgaria and 6 more
- Volunteers
- 30 people
- Sponsor
- Climb Bio, Inc.
Systemic Lupus Erythematosus, Scleroderma
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
This is an open lable and single arm study, is designed to evaluate the safety and preliminary efficacy of HN2301 in Autoimmune Disease（AID）
- Conditions
- Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
- Trial name
- SLE，SSc，RA (NCT06801119)
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Lupus Nephritis
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
The purpose of this study is to characterize the safety and tolerability of ixazomib when administered as multiple oral doses at escalating dose levels in participants with lupus nephritis.
- Trial name
- NCT02176486
- Testing
- Ixazomib
- Where
- 35 sites in United States, France and 5 more
- Volunteers
- 12 people
- Sponsor
- Takeda
Discoid Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid…
- Trial name
- NCT07557927
- Testing
- Dihydroartemisinin tablets, Hydroxychloroquine tablets
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Systemic Lupus Erythematosus
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
The purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while…
- Trial name
- NCT07630714
- Testing
- Anifrolumab + APFS
- Where
- 32 sites in Australia, Belgium and 8 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Discoid Lupus Erythematosus
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with…
- Trial name
- NCT03958955
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 19 sites in United States, Denmark and 2 more
- Volunteers
- 27 people
- Sponsor
- LEO Pharma
Systemic Lupus Erythematosus
Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt
Systemic lupus erythematosus (SLE) is an autoimmune condition characterized by a complicated, unclear etiology that involves various complex factors.
- Trial name
- ROSE (NCT07144514)
- Volunteers
- 276 people
- Sponsor
- AstraZeneca